SUMMARY OF ACCOUNTING POLICIES (Tables)

9 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Schedule of cumulative effect adjustment and the impact on current period financial statements of adopting Topic 606

	Three months ended June 30, 2019 (unaudited)
	prior U.S. GAAP			Topic 606 impact			as reported
Statement of Operations
Revenues
Product	$	392,599		$	-		$	392,599
Service		1,681,065			(20,207	)		1,660,858
Total revenues		2,073,664			(20,207	)		2,053,457
Cost of revenues		270,883			-			270,883
Loss from operations		(1,411,425	)		(20,207	)		(1,431,632	)
	Nine months ended June 30, 2019 (unaudited)
	prior U.S. GAAP			Topic 606 impact			as reported
Statement of Operations
Revenues
Product	$	1,651,928		$	(766,192	)	$	885,736
Service		2,914,956			(84,445	)		2,830,511
Total revenues		4,566,884			(850,637	)		3,716,247
Cost of revenues		564,176			(6,668	)		557,508
Loss from operations		(6,416,455	)		(843,971	)		(7,260,426	)
Assets
Prepaids and other current assets	$	551,178		$	(6,669	)	$	544,509
Liabilities and stockholder's equity
Deferred Revenue	$	452,139		$	350,446		$	802,585
Accumulated Deficit		(254,921,402	)		(350,446	)		(255,271,848	)

Schedule of operations and timing of revenue recognition

	Three Month Period Ended:
	June 30, 2019		June 30, 2018
Research and development services (over-time)	$	1,608,448	$	531,568
Product and authentication services (point-in-time):
Supply chain		161,926		57,017
Asset marking		140,562		264,437
Large scale DNA production		142,521		163,333
Total	$	2,053,457	$	1,016,355

	Nine Month Period Ended:
	June 30, 2019		June 30, 2018
Research and development services (over-time)	$	2,657,560	$	1,230,056
Product and authentication services (point-in-time):
Supply chain		406,543		265,834
Asset marking		469,035		752,105
Large scale DNA production		183,109		459,983
Total	$	3,716,247	$	2,707,978

Schedule of opening and closing contract balances

	Balance sheet classification	October 1, 2018		June 30, 2019		$ change
Contract liabilities	Deferred revenue	$	1,356,502	$	802,585	$	(553,917	)

Schedule of anti-dilutive securities not included computation of net loss per share

	2019		2018
Warrants		16,293,527		12,271,686
Stock options		7,929,446		5,223,221
		24,222,973		17,494,907